Subtype-specific lncRNA signatures: MALAT1 and XIST in breast cancer
Demiroglu Science University Florence Nightingale Journal of Medicine · 29.01.2026 · 11 (3) · 115-121
DOI: 10.5606/fng.btd.2025.206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Demiroglu Science University Florence Nightingale Journal of Medicine, online erschienen am 29.01.2026. Verfasst von Pelin Soytürk.
Abstract (Originalsprache)
Objectives
The objective of this study was to assess and compare metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), and X-inactive specific transcript (XIST) expression among breast cancer molecular subtypes in vitro, and to evaluate their potential association with subtype-specific biological characteristics. Materials and methods: The expression levels of MALAT1 and XIST were analyzed in breast cancer cell lines representing three molecular subtypesluminal A (MCF-7), HER2-positive (MDA-MB-453), and triple-negative (MDA-MB-231)-as well as in non-tumorigenic MCF-10A cells, using quantitative real-time PCR. All experiments were performed in triplicate, and statistical analysis was conducted using one-way ANOVA followed by Dunnett tests.
Results
Both MALAT1 and XIST were significantly upregulated in all breast cancer cell lines compared with MCF-10A control (p
Zitieren
APA
Soytürk, P. (2026). Subtype-specific lncRNA signatures: MALAT1 and XIST in breast cancer. Demiroglu Science University Florence Nightingale Journal of Medicine, 11(3), 115-121. https://doi.org/10.5606/fng.btd.2025.206
Vancouver
Soytürk P. Subtype-specific lncRNA signatures: MALAT1 and XIST in breast cancer. Demiroglu Science University Florence Nightingale Journal of Medicine. 2026;11(3):115-121. doi:10.5606/fng.btd.2025.206
BibTeX
@article{Soytrk2026,
author = {Soytürk, Pelin},
title = {Subtype-specific lncRNA signatures: MALAT1 and XIST in breast cancer},
journal = {Demiroglu Science University Florence Nightingale Journal of Medicine},
year = {2026},
volume = {11},
number = {3},
pages = {115--121},
doi = {10.5606/fng.btd.2025.206}
}
EUVIMED